Equities research analysts expect Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) to report earnings of ($0.90) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Anthera Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.85) and the lowest estimate coming in at ($0.95). Anthera Pharmaceuticals posted earnings of ($4.88) per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 81.6%. The firm is expected to issue its next quarterly earnings results on Friday, November 3rd.
According to Zacks, analysts expect that Anthera Pharmaceuticals will report full year earnings of ($3.65) per share for the current fiscal year, with EPS estimates ranging from ($4.22) to ($3.07). For the next year, analysts forecast that the company will post earnings of ($3.42) per share, with EPS estimates ranging from ($3.92) to ($2.49). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Anthera Pharmaceuticals.
Anthera Pharmaceuticals (NASDAQ:ANTH) last posted its earnings results on Wednesday, August 9th. The biopharmaceutical company reported $0.03 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.09) by $1.12.
Several analysts have commented on ANTH shares. Jefferies Group LLC reiterated a “hold” rating and set a $1.75 target price (down previously from $2.25) on shares of Anthera Pharmaceuticals in a research report on Friday, August 11th. Zacks Investment Research upgraded shares of Anthera Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, June 13th. Finally, ValuEngine upgraded shares of Anthera Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and two have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $10.11.
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Goldman Sachs Group Inc. increased its position in shares of Anthera Pharmaceuticals by 1,376.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 359,982 shares of the biopharmaceutical company’s stock valued at $153,000 after buying an additional 335,595 shares in the last quarter. UBS Group AG increased its position in shares of Anthera Pharmaceuticals by 9.9% in the 1st quarter. UBS Group AG now owns 375,989 shares of the biopharmaceutical company’s stock valued at $160,000 after buying an additional 33,901 shares in the last quarter. Finally, Sabby Management LLC increased its position in shares of Anthera Pharmaceuticals by 1,809.7% in the 1st quarter. Sabby Management LLC now owns 1,757,697 shares of the biopharmaceutical company’s stock valued at $748,000 after buying an additional 1,665,655 shares in the last quarter. Institutional investors and hedge funds own 27.26% of the company’s stock.
Shares of Anthera Pharmaceuticals (ANTH) remained flat at $1.34 on Friday. The stock had a trading volume of 258,645 shares. The firm’s market capitalization is $14.61 million. Anthera Pharmaceuticals has a one year low of $1.20 and a one year high of $27.36. The firm’s 50-day moving average price is $1.36 and its 200-day moving average price is $1.26.
Anthera Pharmaceuticals Company Profile
Anthera Pharmaceuticals, Inc (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Anthera Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anthera Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.